Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Parallel Industries Inc. (EAPH)
Toronto, ON, CA
Currently, Parallel Industries Inc. does not conduct substantial business operations. Historically, the company was involved in developing and commercializing various topically applied medications to treat cancer, alongside other therapeutic solutions for a range of medical conditions. Its strategic emphasis has typically covered the entire pharmaceutical process: from development and licensing to manufacturing and marketing of both prescription and over-the-counter products. Established in 1997, the firm is headquartered in Toronto, Canada, and was formerly known as Easton Pharmaceuticals Inc. before rebranding as Parallel Industries Inc. in December 2020.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +1,900.00% | +1,900.00% | +1,900.00% | +1,900.00% | +1,900.00% | +100.00% | +0.00% | -96.00% | -99.50% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-100.0% Q3'21: +100.0% (vs Q4'19)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+50.0% ★ Q3'21: -106.3% (vs Q4'19)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%—
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%—
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q3'21: -3.6% (vs Q4'19)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q3'21: +1.3% (vs Q4'19)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-298.09× Q3'21: -525.35× (vs Q4'19)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Evan Karras | Chief Executive Officer, President, Secretary, Treasurer, Chief Financial Officer & Director | 150.0K | male |
| Elena Milantoni | Director of Finance and Administration | — | female |
| Lilla Albert | Chief Marketing and Technology Officer | — | — |
| Neil Mellor | Senior Business Consultant, Special Advisor and Member of Advisory Board | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EAPH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
